Science - foundations

Since 2000,  the scientific team associated with Biotranslation have been studying ways to control brain inflammation (substance P). However, our research showed that inhibiting inflammation associated with tumours was linked with anti-tumour action. 

Whilst there is strong pre-clinical evidence (see publications) to support the use of a substance P antagonist in cancer. Since 2004  Dr Munoz (Biotranslation's CMO) has demonstrated effectiveness on substance P antagonist treating cancer patients through compassionate, off-label use. Additionally, demonstrating side effects mitigation associated with either chemotherapy or radiotherapy.

Dr. Munoz and Prof. Nimmo (Biotranslation's CSO) hold over 6,000 scientific citations. They are thrilled to translate years of top research to deliver patient outcomes with the support of a strong professional team and a best in class drug.